STAT3 and autoinflammatory syndrome: For STAT3-mediated conditions, JAK-STAT modulation with ruxolitinib has proven effective in controlling both monocyte overproduction and associated inflammatory cascades, particularly in autoinflammatory syndromes characterized by IL-23/IL-17 axis dysregulation [70].